Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 5 versus FOCALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 5 versus FOCALIN.
ADDERALL XR 5 vs FOCALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR 5 contains a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Dexmethylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations. The d-threo enantiomer of methylphenidate is responsible for the therapeutic activity.
20 mg orally once daily in the morning
Initial 2.5-5 mg orally twice daily, increase by 2.5-10 mg/day weekly; max 20 mg twice daily.
None Documented
None Documented
d-Amphetamine: 10-13 hours (adults), 11-14 hours (children); l-Amphetamine: 13-15 hours (adults). The prolonged terminal half-life of the extended-release formulation supports once-daily dosing.
2-3 hours in children and adults; 4-5 hours in adolescents (due to slower metabolism). Clinical context: t1/2 supports twice-daily dosing (immediate-release) for continuous therapeutic effect
Renal (approximately 90% as unchanged drug and metabolites, with 30-40% as unchanged amphetamine), fecal (minimal, <5%)
Renal: 80% (approximately 50% as unchanged drug, 30% as metabolites); Fecal: negligible
Category C
Category C
CNS Stimulant
CNS Stimulant